| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ... Journal of clinical oncology 26 (8), 1275-1281, 2008 | 3700 | 2008 |
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ... Clinical cancer research 11 (16), 5678-5685, 2005 | 2607 | 2005 |
| The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. L Shi, LH Reid, WD Jones, R Shippy, JA Warrington, SC Baker, PJ Collins, ... Nature biotechnology 24 (9), 1151-1161, 2006 | 2428 | 2006 |
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013 | 2245 | 2013 |
| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 2216 | 2020 |
| Gene-expression signatures in breast cancer C Sotiriou, L Pusztai New England Journal of Medicine 360 (8), 790-800, 2009 | 1968 | 2009 |
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ... Journal of Clinical Oncology 25 (28), 4414-4422, 2007 | 1712 | 2007 |
| Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ... Journal of Clinical oncology 34 (21), 2460-2467, 2016 | 1601 | 2016 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1601 | 2012 |
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in … AU Buzdar, NK Ibrahim, D Francis, DJ Booser, ES Thomas, RL Theriault, ... Journal of clinical oncology 23 (16), 3676-3685, 2005 | 1510 | 2005 |
| The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine JS Ross, EA Slodkowska, WF Symmans, L Pusztai, PM Ravdin, ... The oncologist 14 (4), 320-368, 2009 | 1492 | 2009 |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008 | 1211 | 2008 |
| Cancer heterogeneity: implications for targeted therapeutics R Fisher, L Pusztai, C Swanton British journal of cancer 108 (3), 479-485, 2013 | 1195 | 2013 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1081 | 2014 |
| The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy JS Ross, JA Fletcher, GP Linette, J Stec, E Clark, M Ayers, WF Symmans, ... The oncologist 8 (4), 307-325, 2003 | 972 | 2003 |
| Gene expression profiling in breast cancer: classification, prognostication, and prediction JS Reis-Filho, L Pusztai The Lancet 378 (9805), 1812-1823, 2011 | 936 | 2011 |
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models L Shi, G Campbell, WD Jones, F Campagne, Z Wen, SJ Walker, Z Su, ... Nature biotechnology 28 (8), 827-838, 2010 | 878 | 2010 |
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 856 | 2006 |
| Triple-negative breast cancer—current status and future directions O Gluz, C Liedtke, N Gottschalk, L Pusztai, U Nitz, N Harbeck Annals of Oncology 20 (12), 1913-1927, 2009 | 827 | 2009 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 770 | 2022 |
